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Hypogonadism in older men is a syndrome characterized by low serum testosterone levels and clinical symptoms often seen in
hypogonadal men of younger age. These symptoms include decreased libido, erectile dysfunction, decreased vitality, decreased
muscle mass, increased adiposity, depressed mood, osteopenia, and osteoporosis. Hypogonadism is a common disorder in aging
menwithasigniﬁcantpercentageofmenover60yearsofagehavingserumtestosteronelevelsbelowthelowerlimitsofyoungmale
adults. There are a variety of testosterone formulations available for treatment of hypogonadism. Data from many small studies
indicate that testosterone therapy oﬀers several potential beneﬁts to older hypogonadal men. A large multicenter NIH supported
double blind, placebo controlled study is ongoing, and this study should greatly enhance the information available on eﬃcacy and
side eﬀects of treatment. While safety data is available across many age groups, there are still unresolved concerns associated with
testosterone therapy. We have reviewed the diagnostic methods as well as beneﬁts and risks of testosterone replacement therapy
for hypogonadism in aging men.
1.Introduction
Hypogonadism in older men is a syndrome characterized by
the presence of low testosterone levels and clinical signs and
symptoms of hypogonadism. The symptoms of hypogona-
dism can include decreased libido, impaired erectile func-
tion, muscle weakness, increased adiposity, depressed mood,
and decreased vitality. Hypogonadism is more common in
aging men and is is also referred to as late-onset hypogo-
nadism (LOH) [1], androgen deﬁciency in the aging male
(ADAM) [2], partial androgen deﬁciency in the aging male
(PADAM) [3], testosterone deﬁciency syndrome (TDS) [4],
and andropause [5]. We prefer LOH over the other descrip-
tors.
A signiﬁcant percentage of men over 60 years of age have
serum testosterone levels below the lower limits of young
male adults (20 to 30 years) [6–9]. One longitudinal study
has suggested that approximately 20% of men in their 60s
and approximately 50% of men in their 80s have serum total
testosterone(TT)levelssigniﬁcantlybelowthoseofthelevels
of normal young men [8]. European Male Aging Study
(EMAS)estimatedmuchlowerprevalence(2.1%)ofsympto-
maticlate-onsethypogonadismintheinthepopulation[10].
Several other studies have also noted a decline in TT with
age [11]. In some instances, the clinical symptoms/mani-
festations are more diﬃculttorecognizebecausetheymaybe
masked by comorbid illnesses. There has been some contro-
versy as to the signiﬁcance of falling testosterone levels with
age.Mostexpertsbelievethatitisamedicallysigniﬁcantcon-
dition resulting in signiﬁcant detriment to the quality of life
and adversely aﬀecting the function of multiple organ sys-
tems [6, 11]; while others suggest that it is a chemical marker
of generalized illness [11].
Overthepasttwodecades,signiﬁcantadvanceshavebeen
made in improving the understanding of the pathophysiol-
ogy of the hypogonadism, the diagnostic methods used to
diagnose low testosterone levels, and testosterone replace-
ment therapy. In spite of these advances, a great deal of con-
fusion and misunderstanding still exists among clinicians
and patients about diagnosis of hypogonadism in aging men,2 International Journal of Endocrinology
and beneﬁts and risks associated with testosterone therapy.
In this paper, we have reviewed the studies reported in the
literatureonthissubjectandattemptedtoaddresstheimpor-
tant questions pertaining to hypogonadism in older men. (1)
How to diagnose LOH in aging males? (2) What are the best
treatmentoptionsavailabletodayforclinicianstotreatLOH?
(3) Will older hypogonadal men beneﬁt from testosterone
treatment? (4) What are the risks associated with such an
intervention?
2. Prevalence of Hypogonadismin Aging Males
Several longitudinal and cross sectional studies have been
carried out to determine the prevalence of hypogonadism in
men. Some of the important cross-sectional and longitudi-
nal studies reported include Baltimore Longitudinal Study of
Aging (BLSA), Boston Area Community Health Survey
(BACHS, European Male Aging Study (EMAS), and Massa-
chusetts Male Aging Study (MMAS) [8–10, 12]. These stud-
ies have reported diﬀerent prevalence rates of hypogonadism
in men. The diﬀerences may be in part due to diﬀerent deﬁ-
nitions of hypogonadism adopted by these studies. Variables
include low testosterone level deﬁnition, clinical symptoms
used for the diagnosis of hypogonadism, the population
studied, and the inclusion or exclusion of comorbid condi-
tions in older men.
The actual prevalence of low-serum testosterone in aging
men is not known with certainty, but it is projected to be up
to25%[8,10,13,14].TheEMASnotedano v erallpr evalence
of hypogonadism of 2.1% [10]. The study noted an increase
with age from 0.1% for 40- to 49-year-old men to 5.1%
for 70- to 79-year old men. The MMAS reported that the
overall prevalence of symptomatic androgen deﬁciency was
5.6% with an increased prevalence of 18.4% among 70-year-
old men. In the Boston Area Community Health Survey, the
overall prevalence of hypogonadism was 5.6% among older
men of age 30–79, and the survey also suggested that the pre-
valence among 70-year-old men could be 18.4% [9]. In a
study of men in Hong Kong, the prevalence of symptomatic
hypogonadism was 9.5% with an increased prevalence of
16.7% in the older age group (60–64yrs) [15] .T h eB L S Ar e -
ported that 19% of men over 60 years had low testosterone
levels with the average decline of TT was 3.2ng/dL per year
among men who had an average age of 53 years at entry into
BSLA [8].
A summary of these studies is given in Table 1.S o m eo f
the important ﬁndings of these studies are (1) prevalence
hypogonadisminmen(basedonsymptomsand/ortotaltest-
osterone levels) increases with age starting from the fourth
decade, and (2) the hypogonadism was projected to be much
higher in aging men with comorbidities such as metabolic
syndrome, type 2 diabetes (T2DM), and cardiovascular dis-
ease (CVD). Some other studies have pointed out that much
of the increase in prevalence of hypogonadism with age can
be ascribed to comorbid conditions [16–18].
3.Causes
Hypogonadism can be classiﬁed as primary, secondary, and
mixed hypogonadism. Primary Hypogonadism results from
disorders of the testes that lead to low testosterone produc-
tion and impaired fertility. The laboratory values for patients
with primary hypogonadism show low testosterone and ele-
vated LH and FSH levels. Secondary hypogonadism results
from disorders of the hypothalamus and the pituitary. The
laboratory values for men with secondary hypogonadism
showlowtestosteroneandloworinappropriatelynormalLH
and FSH levels. Mixed hypogonadism can result from dual
defects in the testes and in the pituitary-hypothalamic axis.
Thelaboratoryvaluesformixedhypogonadismcanbevaried
including cases with low testosterone with mild increases in
LH and FSH levels.
Often the type of hypogonadism in older men is either
secondary or mixed hypogonadism. The decline in testos-
terone levels can be due to several factors including (1) de-
cline in Leydig cell function, (2) decline in pituitaryhypo-
thalamic axis function with loss of circadian variation (3) in-
crease in the levels of SHBG, (4) changes in testosterone re-
ceptors sensitivity, and (5) eﬀects of altered cardiometabolic
and inﬂammatory markers [20–22].
Most aging males do not have congenital etiology as their
cause hypogonadism. These congenital processes would
show up much earlier than later in life. Aging males are more
likelytohaveanacquiredcauseoridiopathicetiologyofhyp-
ogonadism.Thediagnosisofhypogonadisminagingmenre-
quires the clinician to evaluate for other causes of secondary
and mixed hypogonadism such as hypothalamic-pituitary
disease, hyperprolactinemia, depression, chronic alcoholism,
diabetes mellitus, and inﬁltrative diseases such as hemochro-
matosisandmedications(e.g.,opioids,anabolicsteroids,and
glucocorticosteroid, opioid analgesics, antidepressants cime-
tidine, spironolactone, and antifungal drugs).
4. Diagnosisof Hypogonadism inAgingMales
Questionnaires have been developed to help identify aging
males with hypogonadism. These questionnaires include (1)
Androgen Deﬁciency in Aging Male (ADAM) questionnaire,
(2) Aging Male survey (AMS), and (3) MMAS questionnaire
[23,24].Whilethesequestionnairescanhavehighsensitivity,
theyhavelowspeciﬁcity[25].Becauseoftheirlowspeciﬁcity,
most guidelines do not recommend their use. A new ques-
tionnaire has recently been validated for hypogonadal men
and its usefulness is not yet established in older men [26].
Testosterone deﬁciency should be conﬁrmed by laboratory
measurements for older men who are identiﬁed as hypogo-
nadal by means of these questionnaires [23, 24]. The Endo-
crine Society Consensus Committee recommends that the
diagnosisofhypogonadismshouldbebasedonidentiﬁcation
of symptoms and signs suggestive of testosterone deﬁciency
and presence of low testosterone levels measured by a relia-
ble assay on two or more occasions [27]. The algorithm sug-
gestedforthediagnosisofhypogonadisminagingmalesdes-
cribed in Figure 1.International Journal of Endocrinology 3
Table 1: Cross-Sectional and Longitudinal Studies of Hypogonadism in Aging Men.
Study Population Results Notes
European Male
Aging Study
(Cross-
sectional)
[10]
3219 men ages 40 to 79
years.
(1) Overall prevalence of hypogonadism was 2.1%.
(2) Hypogonadism increases with age 0.1% (40 to
49yrs) 0.6% (50 to 59yrs), 3.2% (60 to 69yrs) 5.1%
(70 to 79yrs).
(3) Prevalence is higher with increasing number of
coexisting illnesses and BMI
Total testosterone
<320ng/dL (11nmol/L),
and free testosterone
<64pg/mL (220pmol/l).
(LCMS method)
The Baltimore
Longitudinal
Study of Aging
(longitudinal)
[8]
890 men; average age 53.8
+ 16 (samples during time
period 1961 to 1995).
(1) Serum testosterone decreased at a fairly constant
rate, independent of other clinical variables.
(2) Average change of T is about 3.2ng/dL
(−0.124nmol/L) per yr.
(3) Incidence of hypogonadism:: ∼20% in 60s,
∼30% in 70s, and ∼50% in 80s.
Androgen deﬁciency was
deﬁned as total testosterone
less than 325ng/dL. (RIA
method)
The
Massachusetts
Male Aging
Study
(longitudinal)
[12]
1667 men aged 40 to 70 at
baseline (1987–1989).
(1) Crude prevalence of androgen deﬁciency at
baseline and followup is 6.0 and 12.3%.
(2) Crude incidence rate of androgen deﬁciency was
12.3 per 1,000 P-Yr.
(3) Prevalence and Incidence rate increased with
age.
(4) T declines associated with aging −10.1% decline
in TT per decade −23.8% decline in FT per decade.
Total testosterone less than
200ng/dL or total
testosterone 200–400ng/dL
and free testosterone less
than 8.91ng/dL. (RIA
method)
Boston Area
Community
Health Survey
[9]
1475 men ages of 30–79yr;
47.3 ± 12.5yr.
(1) Crude prevalence of symptomatic androgen
deﬁciency was 5.6%.
(2) Prevalence increases with age a. 3.1–7.0% in
men less than 70yr b. 18.4% among 70yr old.
(3) 24% of subjects had total testosterone less than
300ng/dL,
(4) 11% of subjects had free testosterone less than
5ng/dL
Total concentration
<300ng/dL and free
testosterone <5ng/dL.
New Mexico
Aging Process
Study
(longitudinal)
[19]
77 men in the age group
66–80. 15 years of the study
period.
(1) Observed a longitudinal decline in T and an
increase in LH and FSH.
(2) The increasing levels of FSH suggest that
hypogonadism in aging males is probably due to
secondary hypogonadism.
(3) Average rate of decrement in testosterone
concentration is about 11ng/dL (0.382nmol/L) per
year
Note, this study varies in
rate of testosterone decline
from the other studies
Abbreviations: T: Testosterone; TT: Total Testosterone; FT: free testosterone; YRS: years of age; P-Yr: person years; LCMS: Liquid Chromatography tandem
Mass Spectrometry (LCMS); RIA: Radio Immunometric Assay.
The symptoms and signs of hypogonadism in aging men
vary depending upon the age, severity and duration of andro
gen deﬁciency, comorbid illnesses, androgen sensitivity, and
previous testosterone therapy [28]. Symptoms and signs sug-
gestive of hypogonadism (Table 2) include loss of vitality,
visceral obesity, decreased muscle mass and strength, osteo-
penia and bone pain, and mood changes and depression
[1, 2, 5]. Other nonspeciﬁc symptoms are decreased energy,
motivation, and initiative, poor concentration and memory,
sleep disturbance, increased sleepiness, increased body fat,
and diminished physical or work capacity [1, 2, 5, 10].
The measurement of the serum testosterone concentra-
tion is usually the most important single diagnostic test for
male hypogonadism. The important factors that need to be
considered in testosterone measurement are (1) types/forms
oftestosteronetobemeasured,(2)timeofmeasurement,and
(3) frequency of measurement.
Three diﬀerent forms of testosterone can be measured
and they include (a) total testosterone level, (b) free or un-
bound testosterone, and (c) bioavailable testosterone. About
30% to 50% of testosterone is bound to albumin with low
aﬃn i t y .T h ef r e et e s t o s t e r o n ei sa b o u t1 %t o2 % .T h eb i o -
available fractions of testosterone are composed of both the
albumin-boundandthefreetestosterone.Therestofthetest-
osteroneisboundtosexhormone-bindingglobulin(SHBG),
and this portion is not available foruse by most target organs
[21, 27–29].
Measurement of the serum testosterone concentration is
dependent on the time of measurement. In healthy males,
the circadian rhythm aﬀects GnRH secretion and causes test-
osterone levels to change throughout the day. Testosterone
levels are highest in the morning and start to decline by 10
am. The lowest value of testosterone is observed approxi-
mately by 10 PM [30]. The variability between morning and
evening testosterone levels decreases in older men because of
changes to the circadian rhythm. Testosterone levels should
be measured in the morning to obtain peak testosterone re-
sults. If a single morning value is low or borderline low4 International Journal of Endocrinology
Morning total testosterone  
to be hypogonadal)
Followup
Followup
Any reversible cause ?
hypogonadism
No Yes
if one suspects SHBG alteration, 
check free testosterone
and FSH  and FSH
Low  Free T 
do
primary 
hypogonadism 
workup
Inﬁltrative 
disease 
process 
(e.g
check 
Iron, TIBC) 
Primary 
testicular 
failure, 
karyotype
to rule out  
Klinefelter’s
Pituitary 
disease  Age- 
related 
androgen 
deﬁciency  
(LOH)
No
Yes
Repeat total T (am)
Mixed 
Low free T,  
normal LH, and 
FSH do
secondary 
hypogonadism 
workup 
Alcohol, 
glucocorticoids
chronic 
infections 
(HIV), 
Systemic Dz.  
Signs and symptoms of
Normal total testosterone
(if T > 400ng/dl; unlikely (T) (before 10 am)
Low testosterone (< 250ng/dl)
or low normal testosterone
(between 250 to 350 ng/dl)
T >350
T between
250 to 350 ng /dl
Low T (<250 ng/dl)
Check free testosterone
check LH, FSH;
Repeat total T, check LH, FSH;
Nl free T, FSH, LH
10 and 20
20 hypogonadism : low
total T, low/normal LH,
10 hypogonadism :
low total T, high LH,
Low free T,
high LH, and FSH
(prolactin,
other pit.
hormones,
MRI)
hemochromatosis
Figure 1: Algorithm for the diagnosis of hypogonadism in aging males.
or does not ﬁt with the clinical ﬁndings, the measurement
shouldberepeatedonceortwicebeforemakingthediagnosis
of hypogonadism.
ThenormalreferencerangeforTTinadultmenisappro-
ximately 300–1000ng/dL. If the early morning serum TT
level is less than 250ng/dL, the patient is likely to be hypo-
gonadal.ArepeatTTmeasurementisrequiredtoconﬁrmthe
diagnosis. Further evaluation is required if the TT is in the
grey zone of 250 to 350ng/dL. The follow-up tests required
include a repeat of TT levels. One should evaluate the FT
levels when TT values are in the grey zone. If the results indi-
cate a low TT and/or low FT levels, then the patient is hypo-
gonadal. These labs then should be followed with testing of
the serum gonadotrophins (LH, FSH) levels to help ascertain
the anatomical level of hypogonadism (e.g., primary testic-
ular or hypothalamic/pituitary). If a TT level is <150ng/dL
or there are signs or symptoms of possible mass lesion in the
pituitary, then one should order pituitary imaging to exclude
pituitary and/or hypothalamic tumor or inﬁltrative disease.
The diagnosis of hypogonadism in aging men should never
be undertaken during an acute illness as it can result in tem-
porarily low testosterone levels [27, 31].
TT levels can be measured directly by automated immu-
noassays and immunometric assay methods [32–35]. How-
ever, there is a growing concern about the accuracy of auto-
mated immunometric assays especially for measurements in
the low testosterone concentration range [36–38]. Currently,
the most accurate method for determining the TT toInternational Journal of Endocrinology 5
Table 2: Symptoms and associated morbidities with low testos-
terone levels.
Symptoms and associated morbidities
Sexual function Cognition and vitality
Loss of libido Decline in verbal and visual
memory
Erections: reduced quality and
frequency, including nocturnal
erections
Decline in visuospatial
performance
Oligospermia or azoospermia Depressed mood
Gynecomastia/breast discomfort Decreased energy
Changes in secondary hair
characteristics (e.g., shaving) Decline in feelings of initiative
Changes in size of testes Decreased sense of vitality
Decreased fertility
Muscle, bone, and body
composition Other
Progressive decrease in muscle
mass Sleep disturbance
Decreased physical function Lipid abnormalities
Decrease in bone mineral
density; osteopenia,
osteoporosis, increased risk of
bone fractures
Mild anemia (normochromic,
normocytic)
Increase in visceral fat Decreased response to PDE5
inhibitors
diﬀerentiate eugonadal from hypogonadal males is liquid
chromatography-tandem mass spectrometry [38]. Bioavail-
able testosterone is measured by the ammonium sulfate
precipitationmethod.Theequilibriumdialysisisthereferen-
ce method for the measurement of free testosterone concen-
trations [28]. This latter method is very complex and tedious
andthusaroutinemeasurementisonlyavailableinreference
laboratories. Free and bioavailable testosterone concentra-
tions can also be estimated (calculated) from TT and SHBG
concentrations. The calculated FT concentrations derived
from using the law of mass action equations provide a con-
venient and reasonable alternative to equilibrium dialysis
methods [39–41]. The calculations of FT are limited by as-
sumptions made for the equilibrium dissociation constants
(Kd) for the binding of SHBG and T and albumin and T. In
addition, there is no agreed standard for determining the
SHBG. The tracer analog displacement assays that are avail-
able in many hospital laboratories are inaccurate and their
use is not recommended [31].
5. Treatment of Hypogonadism
withTestosterone
There must be a deﬁnitive diagnosis of hypogonadism before
thetreatmentisinitiated.Borderlinetestosteronelevelsalone
are not necessarily an indication to begin testosterone re-
placement therapy. There must be a combination of signs,
symptoms and issues with patient’s quality of life [27, 42,
43]. The goal of testosterone therapy is to raise serum
testosteronelevelintothemidnormalrange(400–700ng/dL)
and resolution or reduction in symptoms of hypogonadism.
However, the ultimate goals of therapy are to reduce disease
and disability, maintain or improve quality of life, and hope-
fully add vitality to the years [44].
The Endocrinology Society Guidelines recommend that
the health care provider considers avoiding testosterone re-
placement therapy in men with certain conditions. The
guidelinesdonotrecommendtestosteronereplacementther-
apy for those who still desire fertility [27]. Aging males with
a history of severe lower urinary tract obstruction, untreated
sleep apnea, prostate cancer, or breast cancer should not be
considered for testosterone replacement therapy [27]. Indi-
viduals with an abnormal digital rectal examination suggest-
ive of cancer, and/or elevated prostate-speciﬁc antigen
should have a careful evaluation by an urologist before con-
sidering treatment. An elevated hematocrit (e.g., >50%) is
also considered to be a relative contraindication for testos-
teronereplacementtherapy[27].Othercontraindicationsin-
clude poorly controlled heart failure and an American Uro-
logical Association International Prostate Symptom Score
(IPSS) >19. Testosterone replacement therapy can be con-
sidered, for individuals that are treated with medications to
decrease the urinary obstructive symptoms of BPH or con-
gestive heart failure.
There are several types of testosterone preparations that
are currently available in the United States including testo-
sterone injections, scrotal and nonscrotal transdermal
patches, oral testosterone, buccal testosterone, and testos-
terone gel preparations. Advantages and disadvantages asso-
ciated with diﬀerent formulations are given in Table 3.C u r -
rently, testosterone injections and testosterone gel prepara-
tions are more commonly used in the United States. Medica-
tions that stimulate the production of endogenous testos-
terone (i.e., hCG, clomiphene) may be used in the treatment
of older men when fertility is an issue.
The buccal testosterone preparation had several draw-
backs including a ﬁxed dose of 30mg and problems with
adhesion of the tablets to the gums [45]. There are men who
have not been able to tolerate the feeling of local presence of
the buccal testosterone tablet. In the United States, an oral
testosterone is currently not in use because preparations
of oral 17-alkylated androgens (e.g., methyltestosterone and
ﬂuoxymesterone) have an increased risk for hepatic toxicity
and abnormal lipid proﬁle (elevated LDL, low HDL) [46].
Oral testosterone undecanoate (TU) is available in many
parts of the world but is not approved for use in the United
States [46, 47]. The presently available oral TU has a short
pharmacokinetic proﬁle and must be taken with food. It
leads to variable serum testosterone levels, elevated DHT/T
ratio, and variable clinical response [46, 47].
There are several intramuscular injectable preparations
available including testosterone enanthate, testosterone cyp-
ionate, and TU. Testosterone enanthate or testosterone cypi-
onate injections can be administered with 200mg every 2
weeks [48–50]. The peak levels of testosterone can be achiev-
ed within 2-3 days after administration of testosterone enan-
thate and cypionate. Serum testosterone levels have to be
measured midway between injections, in individuals that are6 International Journal of Endocrinology
Table 3: Advantages and disadvantages of testosterone preparations.
Administration method Formulation Advantages Disadvantages
Transdermal agents
Testosterone patches
Mimics circadian
rhythm; simple
administration
Skin irritation, occasional allergic
contact dermatitis, daily
administration
Testosterone gel 1-2%
Easy to apply, readily
absorbed into skin.
Flexible-dose
modiﬁcations, skin
irritation less common,
T levels maintained in
normal range.
Transfer during intimate contact;
direct contact with children and
women should be avoided; skin
irritation at the application site in a
small number of men, daily
administration
Underarm
testosterone gel
Skin irritation less
common, T levels
maintained in normal
range
Transfer during intimate contact;
direct contact with children and
women should be avoided, daily
administration
Subcutaneous agents Implants Implants are inserted
every 16 to 24 weeks
Invasive procedure with risk of
extrusion and infection
Intramuscular injections
Testosterone
cypionate Relatively low cost
Pain and redness at injection site;
ﬂuctuations in circulating T levels high
risk of polycythemia;
Testosterone
enanthate Relatively low cost
Pain and redness at injection site;
ﬂuctuations in circulating T levels,
high risk of polycythemia
Testosterone
undecanoate
Less frequent
administration, T levels
maintained in normal
range
Pain at intramuscular injection site
Buccal formulation agents Buccal testosterone
Provides sustained
release of T; through the
buccal mucosa
Unpleasant taste, can stick to gums,
gum pain, or tenderness, headache
Oral formulation agents Methyltestosterone Oral; modiﬁable dosage,
relatively low cost
Potential hepatotoxicity, drug not in
use, may adversely aﬀect lipid proﬁle,
decreasing HDL, and increasing LDL
Testosterone
undecanoate
Oral; (approved in the
Europe)
Variable clinical eﬀects and
testosterone levels must be taken with
meals, nonaromatizable to estrogen,
Underevaluation in the United States
Abbreviations: T: Testosterone; High Density Lipoprotein: HDL; Low Density Lipoprotein: LDL.
on biweekly testosterone enanthate or cypionate injections.
Adjustments to the administration of testosterone dosage
have to be made when T is > 700ng/dL or T < 350ng/dL
[27, 48–51]. The long acting TU injection has been approved
in Europe but it is not yet approved in the United States. It
can be administered in Europe as 1000mg injection with a
loading dose, followed by another injection of TU 1000mg
at week 6, and subsequently administered at every 12 to
14 weeks [51]. The serum testosterone levels rise to supraph-
ysiologic levels for several days and gradually decline over a
period of 10 to 14 weeks after administration of TU injec-
tion [27, 51–53]. The high peak levels can be avoided by ad-
ministering 750mginsteadof1000mgofTUinjections [54].
The levels can be checked prior to each subsequent injection.
The TU injection requires a large volume and can cause
cough in a small number of cases [27, 51–53]. The test-
osterone levels from the longer acting TU cannot be reduced
quickly if PSA levels start to rise. This can pose a risk for an
aging male.
The transdermal method of testosterone administration
has been used as scrotal and nonscrotal patches. Scrotal
patchesarenotcurrentlyusedbecauseoftheneedtoshaveor
cut scrotal hair to maintain adequate patch adhesion to the
skin [51, 55–57]. In addition, some individuals complained
of scrotal itching or discomfort. Transdermal patches can
deliver 5 to 10mg of testosterone. The levels of TT should be
checked 3–12h after application of the patch, and dose ad-
justments should be made to achieve testosterone level in the
midnormal range [51, 55–57]. While nonscrotal patch can
help achieve normal serum testosterone levels with a diurnal
variation, skin irritation can occur in up to 30% of patients
[55–57]. Other drawbacks include the need for up to two
patches per day in some men. A testosterone-in-adhesive
matrix patch is also available. It can deliver approximately
4.8mg of T/d and last for 2 days. Like other transdermal
patches, it can cause some skin irritation [58].
Most testosterone gels are hydroalcoholic-based gels and
contain 1-2% testosterone. The testosterone is absorbed intoInternational Journal of Endocrinology 7
the skin and is slowly released into the body. It allows
for a fairly steady level of serum testosterone that is as
eﬀective as the patch. Testosterone gel is packaged as sachet,
metered pump, or underarm testosterone-gel preparation.
The most widely used testosterone gel can come as 2.5g, 5g,
7.5g,or10ggelwiththeusualdosebeingbetween5–10gper
day. One application of the gel contains 50–100mg of test-
osterone. It is intended to deliver approximately 5 to 10mg
testosterone to the body which can match the normal pro-
duction of testosterone in healthy men. The dose adjustment
of testosterone gel can be done after a patient has been treat-
ed for at least one week to achieve serum testosterone level
in the midnormal range. Testosterone gel has minimal skin
irritability. However, they is a potential of transfer of testo-
sterone to others upon close skin contact. Transfer of testo-
steronecancauseclinicalvirilizationinfemalesandchildren,
andthiscanbeminimized byshowering orwearingclothing.
Of the transdermal testosterone preparations, the gel for-
mulation is currently recommended for most hypogonadal
m e n .T h eg e lf o r m u l a t i o ni sa b l et op r o d u c eas t e a d ys e r u m
testosterone concentration within the physiological range of
adult men. Some men who desire freedom from daily appli-
cationorlowercostcanuseintramuscularinjectionsoftesto-
sterone. Oral testosterone formulations that do not have side
eﬀects of prior oral drugs are under development.
Aging males who are started on testosterone replacement
therapy should be followed periodically. After the initiation
of testosterone replacement therapy, subjects should have a
clinic visit, within 3 months, to make needed dosage and for-
mulation adjustments. Subjects should have regular visits (3
to 6 months after treatment initiation and then annually) for
assessment of symptom improvement [27]. The visits should
also focus on evaluating for erythrocytosis, prostate disease,
diﬃculties with sleep apnea, and other adverse events. The
urinary frequency or voiding diﬃculties can be aﬀected by
prostate size. The International Prostate Symptom Scale
(IPSS)canbeusedtomonitorforchangesbyusingitatbase-
line and subsequent visits. An IPSS prostate symptom score
of >19 should warrant a urological consultation [27]. In ad-
dition to TT levels, lab tests should include measures of liver
function, hemoglobin, hematocrit, and PSA. A hematocrit is
to be evaluated at baseline, 3 to 6 months, and then annually.
When hematocrit rises above 54%, one should cease testos-
terone replacement therapy until hematocrit decreases to a
safe level before reinitiating therapy at a lower dose as noted
in the recent Endocrine Society Guidelines [27]. The patient
with signiﬁcantly elevated hematocrit should be monitored
and evaluated for symptoms of sleep apnea, cardiovascular
events, and hypoxic complaints.
6. Possible Beneﬁts of Testosterone Therapy
In the past two decades, several studies have been carried out
todeterminethebeneﬁtsoftestosteronereplacementtherapy
for hypogonadal men. The results of these studies indicate
that testosterone therapy provides several beneﬁts including
improvements in muscle mass and strength, bone min-
eral density (BMD), adiposity, lipid abnormalities, glucose
control, cardiovascular disorders, sexual function, mood,
and cognitive function. A summary of the beneﬁts of testo-
sterone therapy for aging hypogonadal males is given below.
6.1. Muscle Mass and Strength. In aging males, falling testo-
sterone levels have been associated with declining strength
and muscle mass [59, 60]. The New Mexico Aging Process
Study also noted correlations between total and free testos-
terone levels and muscle strength [19, 61]. A cross sectional
study of 118 men on androgen deprivation therapy for pro-
state cancer showed impaired physical and functional mus-
culoskeletal performance when they were compared with
age-matched controls who were not hypogonadal [62].
Several studies found testosterone replacement therapy
tobebeneﬁcialinimprovingmusclestrengthinhypogonadal
older men. Svartberg et al. noted an improvement in hand
grip in older men with TU treatment [63]. Page et al. found
improvements in both hand grip and physical function for
hypogonadal men that were on testosterone enanthate treat-
ment [64] .Am o d e s ti n c r e a s ei nm u s c l em a s sa n da n
improved leg extensor strength were also observed in some
studies [65, 66]. A double-blinded placebo-controlled study
found that elderly men on testosterone replacement therapy
for 6 months improved their lower limb muscle strength
(isometric knee extension peak torque) when compared
with subjects on placebo [67]. The improvement in muscle
strength was accompanied by other measurable beneﬁts in
gait and balance, aggregate locomotor function test, physical
performancetest,and6-minwalktestat6-monthassessment
in the testosterone group [67]. However, the improvements
in muscle strength did not result in signiﬁcant changes
in functional ability. Meta-analyses of randomized trials in
middle-agedandoldermenhaveconﬁrmedthattestosterone
administration is associated with an increase in lean body
mass (LBM), reduction in fat mass, and increase in grip
strength when compared with placebo.
Some other studies did not observe any signiﬁcant im-
provements in muscle strength with testosterone therapy. A
small study by Clague et al. found no signiﬁcant improve-
ments in handgrip strength, isometric strength of knee ﬂex-
ors, and extensors or leg extensor power [68]. Meta analysis
studies by Isidori et al. also did not ﬁnd any signiﬁcant im-
provement in muscle strength when middle-aged men were
treated with testosterone replacement therapy [69]. Similar
resultswerereported byNair et al.withtestosteronepatchre-
placement study in elderly men [70].
Physical function is aﬀected by many factors including
muscle strength. Improvements in physical function have
also been studied. Changes in performance-based measures
of physical function have been inconsistent across testoster-
onetrialsthatrecruitedhealthyoldermen.Testosteronether-
apy did not signiﬁcantly aﬀect overall quality of life scores
[27, 71]. However, a Spanish study conﬁrmed that physical
function and the ability to participate in physical activity
safely are related to feelings of well being in the elderly [72].
Thelong-termbeneﬁtoftestosteroneonfunctionalimprove-
ments requires further investigation.8 International Journal of Endocrinology
6.2. Bone. Testosterone plays an important role in BMD by
increasing osteoblastic activity and reducing osteoclastic
activity [73–75]. Some of the androgen eﬀects on bone are
partially indirect. The reduction in osteoclastic activity ap-
pears to be mediated via testosterone’s aromatization prod-
uct to estradiol (e.g., eﬀects on cortical bone) [73–78]. There
appears to be associations between testosterone levels and 25
(OH)VitaminDlevelsandtestosteroneandphosphatelevels
[79, 80]. There is a strong association between low bone den-
sity, bone loss, osteoporosis, and low testosterone levels in
aging males [81, 82]. There has also been an association of
increased risk of fractures in men with hypogonadal states
[83–85].
Testosterone replacement therapy was found to increase
bone density in hypogonadal men [63, 86] .T h eb o n ed e n s i ty
increases, however, it may not reach normal adult bone mass
[87]. Meta-analysis studies have shown testosterone replace-
ment therapy positively aﬀects bone density and reduces the
rate of bone loss [69, 88]. Testosterone therapy appears to
have a positive eﬀect on bone markers with a reduction in
bone resorption markers [24, 69]. While a few studies have
not shown a clear beneﬁt in bone density, many studies with
exogenous testosterone have noted increases in BMD in
hypogonadal aging males [89, 90]. The improvement in
BMD was noted in most types of exogenous testosterone ad-
ministration including the more commonly used gel prepa-
rations [70, 91].
Some studies have reported improvements in lumbar
bone density [63, 91–93]. This has also been noted in the
meta-analysis by Tracz et al. [88] and Isidori et al. [69]. The
studies by Wang et al. [91], Amory et al. [90] and Nair et al.
[70] suggested improvements in hip BMD while the meta-
analysisstudiesbyTraczetal[88]andIsidorietal.[69]found
femoral neck improvements to be inconclusive. While BMD
improves, the eﬀect of testosterone replacement therapy on
fracture risk is still unclear. None of the studies have been
large enough to show a fracture risk reduction with testoster-
onereplacementtherapy.Further,investigations arerequired
to conﬁrm the long-term beneﬁts of testosterone therapy for
improving bone strength and its properties.
6.3. Adiposity, Lipid Abnormalities, and Glucose Metabolism.
Men with obesity, metabolic syndrome, and type-2 diabetes
have low total and free testosterone and low sex hormone-
binding globulin (SHBG). Low testosterone is associated
with dyslipidemia, hypertension, obesity, and diabetes, all of
which increase the risk of cardiovascular disease [93, 94]. It
appears that testosterone levels are involved with obesity in a
complex relationship. Testosterones levels could be as a cau-
salfactorofobesityandcouldalsobeaconsequenceofexcess
adipose tissue itself. A meta-analysis of observational studies
notedthatmaleswithmetabolicsyndromehadlowerTTand
free testosterone levels [94].
Obesityhaseﬀects on the hypothalamus, pituitary gland,
and testes with resultant hormonal abnormalities [95]. An
increase in regional adiposity appears to be related to levels
oflowtestosterone[96].ThiscanbeassociatedwithlowerTT
and sex hormone-binding globulin in obese individuals
when compared with nonobese individuals [10, 95]. It ap-
pears that there is a negative correlation between serum TT
and FT levels and visceral fat mass [97, 98].
Several studies have noted that testosterone replacement
therapy results in a reduction of body fat mass and waist cir-
cumference in hypogonadal men with and without obesity
[99, 100]. The studies have also noted some positive changes
in total body fat and regional fat distribution with testoster-
one replacement therapy [95, 100–102]. Adiposity was also
noted to decrease along with an increase in lean body mass
in a muscle function trial of hypogonadal men in the testo-
sterone-treated group [67]. BMI improved in only one trial
[103] and body fat decreased in other studies [104, 105]. It
has also been noted that the leptin levels correlate with body
fat content and leptin levels decrease with testosterone
replacement in T2DM and metabolic syndrome [104, 106].
Severalstudiesindicateadecreaseincentraladiposityinmen
with metabolic syndrome and/or T2DM with testosterone
treatment [103, 104, 107].
Testosterone plays a role in lipid metabolism. It does
aﬀect the actions of lipoprotein lipase and lipolysis [108].
Low testosterone levels can lead to changes in triglycerides
and high-density lipoprotein cholesterol. It can also aﬀect
totalcholesterollevels[69].Theeﬀectoftestosteroneonlipid
proﬁle was investigated in several studies including those on
coronary heart disease, metabolic syndrome, and diabetes
[100]. Testosterone therapy results in a small but signiﬁcant
fall in total cholesterol and in some LDL cholesterol [100,
105, 107]. In one study, it was noted that the use of
testosterone showed a dose-dependent trend toward lower
HDL, LDL, and total cholesterol [109]. Most reports found
nochangeintriglycerides.However,onemeta-analysisnoted
that the testosterone and placebo/nonintervention groups
did not diﬀer signiﬁcantly in the changes from baseline in
total cholesterol, low-density lipoprotein (LDL), and triglyc-
erides [110]. The observed decrease in LDL in a number of
studies may be of some beneﬁt to individuals with hypogo-
nadism and other cardiovascular risk factors. In general, the
eﬀectsonlipidsareobservedmoreafteroral-andhigher-dose
testosterone treatment. The eﬀects are less with transdermal
preparation and lower doses of replacement.
Hypogonadism with low total or free testosterone cor-
r e l a t e sw i t hl o wH D Lc h o l e s t e r o l[ 111]. The MMAS study
notedastrong,positive relationshipbetweenHDLandtesto-
sterone in men with CVD [111]. However, treatment with
testosterone does not seem to increase HDL. Some studies
have observed that supraphysiologic doses of testosterone
will lower HDL [110, 112]. High-density lipoprotein (HDL)
cholesterol levels were also found to decrease in patients that
were on oral testosterone therapy [57, 113]. In a meta-anal-
ysis study, the high-density lipoprotein (HDL) cholesterol
levels were signiﬁcantly lower in the testosterone-treated
group than the control group [110]. There is some evidence
that after an initial decrease, HDL cholesterol levels then
return to baseline [105]. It is concerning to note that any car-
diovascular beneﬁt in lowering LDL is tempered by unde-
sired changes to HDL levels.
There have been studies that have noted associations
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metabolic syndrome. Low testosterone concentrations have
been noted in individuals with T2DM [17, 114]. This was
also noted in a review of the NHANES database [115]. While
individuals with T2DM did not appear to have linear cor-
relations between testosterone concentration and degree of
glucose control, studies with testosterone treatment in hypo-
gonadal men have shown some reductions in glucose levels
and insulin resistance [103, 107, 114, 116]. Wang et al. has
stated that the mechanisms that connect hypogonadism,
insulin resistance, and T2DM are complicated and include
inﬂammatory markers, oxidative stress, and many other pos-
sible underlying causes [117]. A mechanistic paradigm that
may be involved between testosterone, obesity, and T2DM
has been reviewed by Wang et al. [117].
The eﬀects of testosterone on insulin sensitivity and glu-
cose control have been noted in studies. Low TT or SHBG
levels are associated with T2DM [118, 119]. Marin et al. re-
portedthattestosteroneimprovedinsulinsensitivityassessed
by euglycemic insulin clamp studies in obese men while re-
duc-ing central adiposity [99]. A randomized double blind
crossover trial demonstrated a signiﬁcant reduction in in-
sulin resistance in hypogonadal men with T2DM on testos-
terone replacement therapy [107]. Several other studies have
also shown that testosterone therapy improves insulin sensi-
tivity in hypogonadal men with and without T2DM [117].
Another study has noted improvements in insulin sensitivity
once testosterone levels were normalized [120]. In one study,
healthy men who had induced hypogonadism had a reduc-
tionininsulinsensitivitywhentherewasanacutewithdrawal
oftestosterone[121].AsmalllongitudinalstudyofTUversus
placebo noted improvement in fasting glucose and decreased
insulin resistance in the TU group [122]. The improvements
in insulin sensitivity and glucose control are corroborated
in other studies which also noted improvements in HOMA
when hypogonadal men with metabolic syndrome and/or
T2DM were treated with testosterone replacement therapy
[70–72]. A prospective trial, by Jones etal., reported that
hypogonadal men with metabolic syndrome and/or T2DM
on transdermal TRT had reductions in HOMA-IR in addi-
tion to beneﬁcial eﬀects on total and LDL-cholesterol and
lipoprotein-a [105]. Improvements in hemoglobin A1C
(HbA1C is a glycated hemoglobin that reﬂects average
plasma glucose concentration over several weeks) were also
observed in two trials [103, 107]. A meta-analysis study has
also noted improvements in fasting plasma glucose, and
HOMAinthetestosterone-replacementtherapygroup[118].
Thesestudiessuggestthenormalizingtestosteronelevelsmay
be helpful in individuals who have T2DM and hypogo-
nadism.
6.4. Cardiovascular Disease. High levels of testosterone do
not contribute to the etiology of cardiovascular disease and
increased incidence of coronary atherosclerosis in men
undergoing coronary angiography [123, 124]. However, car-
diovascular risk factors may be aﬀected by the presence
of low testosterone levels. Low testosterone is associated
with dyslipidemia, hypertension, obesity, and diabetes, all
of which increase the risk of CVD [125, 126]. Lower
testosterone levels were associated with adverse changes to
carotid intima medial thickness and ankle/brachial index as
a measure of peripheral arterial disease and calciﬁc aortic
atheroma [127–129].
Some observational studies show a correlation between
low testosterone and CVD, and others show no correlation.
Several epidemiological studies have noted that low testos-
terone levels were associated with increased mortality in
older men [130–135]. In contrast, some studies such as the
MMAS study did not show that TT levels were clearly related
to all-cause mortality [136, 137].
Aging males are at particular risk for CVD. There are
studies that testosterone therapy may be beneﬁcial in several
ways. English et al. were the ﬁrst to report that testosterone-
replacement therapy may be beneﬁcial for men with cardiac
disease [138]. They found that 22 men with chronic stable
angina who were treated with transdermal testosterone-re-
placement therapy had greater angina-free exercise tolerance
than 24 placebo-treated controls. TRT administration in
hypogonadalmenwasreportedtoimproveexercisetolerance
(decreased exercise-associated ischemia) in aging males with
coronary artery disease [139]. A small longitudinal study of
TUversusplacebonotedimprovementsinthecarotidmedial
thickness in the TU group [122]. Testosterone treatment was
also found to decrease lipoprotein—A levels in subjects with
metabolic syndrome and or T2DM [105, 140]. Another ran-
domized control study showed testosterone treatment in
elderly patients with chronic heart failure improved various
cardio, respiratory, and muscular outcomes [94, 141].
A meta-analysis study showed no signiﬁcant diﬀerences
in the rates of death, myocardial infarction, revascularization
procedures, or cardiac arrhythmias between the testosterone
and the placebo/nonintervention groups [110]. Another
meta-analysisalsofoundnoassociationbetweentestosterone
replacement therapy and cardiac events [142]. However,
these meta-analyses trials of testosterone therapy generally
have not been designed or adequately powered to detect
eﬀects on clinically signiﬁcant cardiovascular events [143].
Other studies of testosterone-replacement therapy have not
demonstrated an increased incidence of cardiovascular dis-
easeoreventssuchasmyocardialinfarction,stroke,orangina
[144]. However, the true beneﬁts of normalizing testosterone
levels in aging hypogonadal men who have underlying car-
diac disease are not fully understood and require further in-
vestigation.
6.5. Sexual Function. When plasma testosterone levels are
below a minimum level, many aging men experience sym-
ptoms of low libido, changes in erectile function, and possi-
bly changes in morning erection frequency [145]. Low testo-
sterone levels can lead to reduced sperm production (oligo-
spermia), decreased libido and sexual satisfaction, and
strengthoferectionsinelderlymen.Inhypogonadalyounger
males, the restoration of serum testosterone levels to the nor-
mal levels show beneﬁts on sexual function outcomes [146].
Therearereportsofimprovementsinsleep-relatederections,
cavernous venous leakage, and enhancing production of
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therapy [147–149]. Many studies in younger men have re-
ported improvements in libido in the testosterone-treated
groups when compared with placebo groups [144]. While
improvementsinlibidoappeartobemoreconsistent,theim-
provements to erectile function appear to be varied among
trials [150–152]. The meta-analysis study by Isidori et al. re-
ported that moderate improvement in sexual function was
noted in men with testosterone levels below 346ng/dL [152].
The overall impact on sexual satisfaction, however, appears
t ob eu n c l e a ra st od e g r e eo fi m p r o v e m e n ta f t e rt e s t o s t e r o n e
replacement therapy [151]. Long term studies are required
to further evaluate the eﬀects of testosterone-replacement
therapy on erectile function in older men.
6.6. Mood. Aging hypogonadal men are at increased risk for
developing depression [153]. In hypogonadal men, testos-
terone replacement was associated with improved mood and
feelingsofwellbeing[44,154–156].Despiteimprovementsin
mood with testosterone-replacement-gel therapy, the beneﬁ-
cial eﬀect from concomitant testosterone-replacement ther-
apy and SSRIs cannot be clearly diﬀerentiated [157, 158]. A
meta analysis showed some beneﬁcial eﬀects of testosterone
replacement therapy on depression scores [159]. Testoster-
one replacement therapy’s beneﬁcial eﬀects on quality of life
and depressive mood have not been consistent across trials
[138,154].Meta-analysisstudiesandreviewsofandrogenre-
placement therapy do not appear to support testosterone re-
placement as an antidepressant for the general population
[160, 161]. Additional studies are needed to assess the eﬀects
of testosterone on clinical depression.
6.7. Cognitive Function. The impact of testosterone on
aspects cognitive function has been studied in trials [162–
164] .L o w e rl e v e l so ft e s t o s t e r o n ea p p e a rt oh a v ea ne ﬀect on
abilitiessuchasspatialabilities,verbalabilities,andcognitive
function [162–166]. This is of particular importance to the
aging male who may experience changes in cognitive ability
fromothercomorbiditiessuchasvasculardiseaseandneuro-
logical pathology.
The eﬀects of testosterone replacement therapy on mea-
sures of cognitive function and memory have shown mixed
results [167, 168]. In studies by Janowsky et al., Cherrier
et al., and Tan and Pu, testosterone replacement improved
verbal and spatial memory and constructional abilities in
nonhypogonadal men with mild cognitive impairment,
hypogonadal men and Alzheimer’s disease [165, 166, 169–
171]. Transdermal testosterone treatment (5 to 10mg of
testosterone) of men aged 34 to 70 years appears to improve
theirverbalmemoryandspatialmemory[170,171].Another
study of healthy men aged 50 to 90 years investigated the eﬃ-
cacy of intramuscular testosterone (alone or in combination
with the aromatase inhibitor anastrozole) in improving the
cognitivefunction.Thisstudynotedimprovementsinspatial
memory in both groups but verbal memory only improved
in testosterone-treated men without anastrozole [171]. The
beneﬁcial eﬀects on cognition, memory, and visuospatial
abilities were not seen in other randomized studies [172–
175]. The evidence in support of and against the improve-
ments in cognition, memory, and visuospatial abilities is not
uniform. This could be in part due to the short duration and
smaller sample size. Randomized control trials of a longer
duration are needed particularly in older hypogonadal men
who are on testosterone replacement therapy to fully ascer-
tain the beneﬁts on cognitive performance.
7. Possible Risks of Testosterone Therapy
for Elderly Men
Testosteronereplacementtherapyshouldbeutilizedwithfull
awareness of both its potential beneﬁts and possible risks.
Several clinical studies have been carried out to determine
the potential risks associated with the testosterone therapy to
various organs including cardiovascular, respiratory, blood,
prostate, and testes. Many of these studies were based on
limitednumberofsubjectsandofshorttomediumduration.
In spite of these limitations, these studies have identiﬁed
several potential risks associated with the testosterone ther-
apy. Some of the potential risks include possible eﬀects on
cardiovascular complications, sleep apnea, polycythemia,
and prostate cancer.Elderly men seem to be at increased risk
for ﬂuid retention, increased risk of polycythemia, changes
in sleep apnea, and acceleration of benign or malignant pro-
staticdisease[5].Testosterone-replacementtherapyisnotre-
commended for those who still desire fertility. A brief review
ofsomeofthemainconcernsassociatedwithtestosteronere-
placement therapy is given below.
7.1. Cardiovascular Disease. In the near past, there was a
prevailingideathatandrogenscanhaveanatherogeniceﬀect.
This concern arose from the observation that aging men had
higher incidence of CVD compared to aging women. Andro-
gen administration drew a concern because it could subseq-
uently add to the risk of developing CVD in men because
there were already higher levels of testosterone in aging men
compared to aging women. Over the last decade several
papers have examined the relationship of androgens with
CVD. Many of these studies suggest that there may be even
neutral to beneﬁcial eﬀect of testosterone-replacement ther-
apy on the cardiovascular risk factors and adverse cardio-
vascular complications (e.g., angina) [142, 176–179]. Testos-
terone replacement is not without risks for the aging males.
TRT can lead to water retention and edema [176]. However,
in one interventional trial, there were an increased number
of cardiovascular-related adverse events in a population of
oldermenwhohadsigniﬁcantchronicdiseaseandwithlimi-
tations with mobility [180]. However, such an increase was
not noted in another study on testosterone treatment in frail
older men [67]. We need longitudinal studies that will assess
coronary artery changes to help us attain a better under-
standing of the eﬀects of testosterone-replacement therapy
on the cardiovascular system in aging hypogonadal men.
7.2. Sleep Apnea. Obstructive sleep apnea syndrome (OSA)
can result in hypoxemia, sleep fragmentation, and excessive
daytime sleepiness [181, 182]. Individuals with OSA can
have an increased incidence of visceral obesity, insulin resis-
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as atrial ﬁbrillation, stroke, and cardiac ischemia [181, 183].
OSA and metabolic syndrome are also associated with in-
creased incidence of reduced-circulating testosterone values
anderectiledysfunction[184–186].Androgensmayplayrole
incontributingtothepathogenesisofobstructivesleepapnea
as there are associations between men with abnormal sleep
patterns and increased visceral adiposity with low plasma
testosterone values [187, 188]. The presence of low testos-
terone levels with preexisting OSA can further complicate
cardiometabolic risk factors.
Someearlystudieshavesuggestedsupraphysiologicdoses
of testosterone seem to be more often associated with exa-
cerbation of OSA [189–191]. Elderly individuals who are not
treated for OSA should not be started on TRT till OSA is
treated. This is because of the increased risk of polycythemia
and its possible eﬀects on other comorbid conditions.
Individuals with treated OSA and hypogonadism have
been considered for testosterone-replacement therapy. In a
meta-analysis of placebo-controlled trials of testosterone-re-
placement therapy to aging men, they found that there was
no signiﬁcant diﬀerence in frequency of sleep apnea between
the placebo and testosterone-replacement therapy groups
[101]. A small study has noted that testosterone-replacement
therapy in individuals with idiopathic hypogonadotropic
hypogonadism improves slow wave sleep and does not in-
crease the frequency of OSA [192]. Another study noted that
testosterone replacement therapy appears to improve erectile
dysfunction in men with OSA and hypogonadism [187].
Even though small studies have shown beneﬁts of testoster-
one-replacement therapy for individuals with OSA, one
should exercise caution in giving testosterone-replacement
therapytoindividualswithsevereuntreatedorpoorlytreated
OSA [27, 101, 191]. Further longitudinal studies are needed
to ascertain the eﬀects of testosterone-replacement therapy
in men with hypogonadism and OSA.
7.3. Polycythemia. Men with hypogonadism have lower
hemoglobin levels than age-matched controls. The anemia,
observed in the aging hypogonadal men, has been suggested
to be partly due to declining testosterone levels and also
partlyduetoeﬀectsonerythropoietin anderythroidprogen-
itor cells [193–196]. Testosterone-replacement therapy can
restore the hemoglobin levels of older men to the normal
range. There appears to be a direct relation between testo-
sterone dosage and the incidence of erythrocytosis with test-
osterone gel [157]. This dose-dependency was noted in ano-
ther study [57], which compared the eﬀects of transdermal
versus intramuscular testosterone. It was noted that the
intramuscular testosterone raised the hematocrit more than
transdermal testosterone. The dose dependency was also
seen in testosterone pellets [197]. The stimulation of hema-
topoiesis has been noted to be inﬂuenced by age and appears
to be more pronounced in older men [198, 199].
Although an increase in the hematocrit is generally bene-
ﬁcial for hypogonadal men with anemia, an elevation of
hematocrit above the normal range may lead to an increase
in blood viscosity. The elevations in hemoglobin can result
in adverse outcomes, particularly in elderly due to increases
in viscosity that can exacerbate vascular disease (coronary,
cerebrovascular, or peripheral vascular circulation) [27, 193,
200–202]. Individuals with increased blood viscosity have
beenknowntobeatanincreasedriskforthromboticcompli-
cations such as stroke, myocardial infarction, deep vein thro-
mbosis, stroke, and pulmonary embolism [203–208]. This
ﬁnding has raised awareness of the importance of monitor-
ing hematocrit when on testosterone-replacement therapy.
While there are legitimate concerns regarding polycythemia
in individuals with testosterone supplementation, there is no
clear evidence of signiﬁcant complications in a recent meta-
analysis of placebo-controlled trials [101].
The risk of polycythemia can be managed through care-
ful monitoring of individuals on testosterone treatment [27,
180, 194, 209]. Individuals who are on testosterone-replace-
ment therapy need a check of their hematocrit levels every
3 to 6 months and then annually [27]. The testosterone-re-
placement therapy should be held if the hematocrit is ≥54%
until the hematocrit can return to a safe level; subsequently
testosterone-replacement therapy is reinitiated at a reduced
dose [27]. It is recommended that individuals with baseline
hematocrit values (pre initiation of treatment with testos-
terone replacement therapy) above 50% should undergo a
workup prior to testosterone-replacement therapy because
thesemenhaveanincreasedchanceofdevelopinghematocrit
levels above 54% [27].
7.4. Prostate. There are reports of metastatic prostate cancer
after testosterone administration in (elderly) men [210–
212]. This has raised concern that testosterone-replacement
therapy should be given to aging men who do not have signi-
ﬁcantly high risk of developing prostate cancer. The current
Endocrine Society Guidelines have been developed to render
testosterone administration to elderly men acceptably safe
therapyinmenwithoutapriorhistoryofprostatecarcinoma
or without evidence of harboring a prostate carcinoma [27].
The concern for prostate cancer has led to the relative
contraindication of testosterone-replacement therapy in
some individuals [27]. If an individual’s medical history re-
veals an increased risk of prostate cancer (e.g., African-
Americans or men with ﬁrst-degree relatives with prostate
cancer) with PSA levels that are greater than 3ng/mL, then
the subject should have a workup with an urologist or other
physician experienced in prostate gland evaluation. A work-
upwithanurologistisalsowarrantedinindividualswithpal-
pableprostatenoduleorinduration. Cautionshouldbeexer-
cised in men over 40 years of age with increase in PSA con-
centrationgreaterthan1.4ng/mLwithina12-monthperiod,
elevated PSA levels (>3o r>4ng/mL), or with high-risk pro-
state history. These individuals need to be evaluated with a
digital rectal examination of the prostate to look for nodules
and enlargement [27].
Whiletherearerelativecontraindicationstotestosterone-
replacement therapy, most studies (using diﬀerent testoster-
one formulations over periods ranging from several months
to 15 years in men with a wide range of ages) have not reveal-
ed an increased risk of prostate cancer [148, 213–215]. A
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compared to placebo was not associated with a signiﬁcantly
higher risk of prostate cancer [101]. Two small studies have
reported no signiﬁcant prostate-speciﬁc antigen (PSA) rise
or prostate cancer recurrence in a total of 17 men, following
radical prostatectomy in men with undetectable PSA [216,
217]. Another small study reported no cancer recurrence in
31 hypogonadal men treated with brachytherapy with a fol-
l o w u po fa p p r o x i m a t e l y5y e a r s[ 218].
7.5. Other Potential Adverse Eﬀects of Testosterone-Replace-
ment Therapy. Due to an imbalance in the testosterone to
estrogen ratio, hypogonadal men have reported experiencing
softer testes, gynecomastia, and increased visceral obesity.
Testosterone-replacement therapy does appear to be helpful
in men to reduce some of these eﬀects such reduced vis-
ceral obesity [107]. However, some men have reported ad-
versephysicalchangesintheirbreast,testes,andskinafterre-
ceiving testosterone-replacement therapy [5].
The increase in serum testosterone levels can suppress
gonadotrophin release from the pituitary. The reduction in
the production of intratesticular testosterone can also lead to
reduced sperm production. Men should be advised that fer-
tility can be adversely aﬀected during testosterone-replace-
ment therapy [219]. When men become hypogonadal, there
is an alteration in the free estrogen to free androgen ratio
and this can aﬀect the breast [220]. Some men have noted
experiencing breast tenderness and swelling or worsening
breast tenderness in men with preexisting gynecomastia. The
evidence for this association, however, is considered to be
weak.
A change in testosterone levels through the use of testo-
sterone replacement therapy appears to aﬀect the skin and
hair in men. Some men have noted increased oiliness of skin
and acne. The increases in testosterone levels following testo-
sterone-replacement therapy can increase secretion of sebum
[221, 222]. This can increase the incidence of minor incon-
veniences such as the reappearance of acne and oiliness of
skin.Whilethereareanecdotalreportsofchangesinhairpat-
tern, it has not been extensively reported in randomized
double blind control trials. The transdermal formulations of
testosterone replacement therapy can have administration
speciﬁc skin reactions. Individuals who have used gels and
patches have complained of skin irritation. However, there
are more complaints of skin irritations (e.g., erythema, pru-
ritus)thathavebeenreportedwithpatchesthanwithgelpre-
parations [223]. Intramuscular injections of testosterone can
cause local reactions such as soreness, erythema, and bruis-
ing [224, 225]. The adverse aﬀects of diﬀerent formulations
are listed in Table 3.
8. Summary andRecommendations
Longitudinal studies have shown that prevalence of hypogo-
nadism in the aging men is increasing with each additional
decade. Hypogonadism in older men is a syndrome chara-
cterized by low serum testosterone levels and clinical symp-
tomsoftenseenin hypogonadal menofyoungerage.Thepa-
tient is likely to be hypogonadal if the early morning serum
totaltestosteronelevelislessthan250ng/dL.Sincetheserum
testosterone threshold for a given symptom may vary among
symptoms and individuals, it is possible that this threshold is
too low in some cases. More large scale data are required to
clarify this uncertainty. Aging men with hypogonadism may
experiencemanysymptomsincludingdecreasedsexualfunc-
tion, decreased cognitive function, elevated LDL in the lipid
proﬁle, increased visceral adiposity, changes to the bone den-
sity and strength, and muscle weakness and atrophy. Late-
onset hypogonadism may also have eﬀects on diabetes and
the cardiovascular system. The Endocrine Society Guidelines
recommend that one should have symptoms of androgen
deﬁciency and low testosterone levels for the diagnosis
of hypogonadism. These guidelines also recommend that
testosterone levels should be measured on more than one
occasion and the samples for analysis need to be obtained
in the morning before 10 am. The diagnosis of late-onset
hypogonadism can be less certain in aging men who have
comorbid conditions with borderline low testosterone levels.
Several testosterone formulations have been developed
for treatment of hypogonadism, and these formulations
include testosterone injections, transdermal patches, oral
testosterone, buccal testosterone, and transdermal testos-
terone gel preparations. Currently, testosterone injections
and testosterone gel preparations are more commonly used
in the United States. Limited clinical trials carried out with
these medications indicate that testosterone-replacement
therapy provides signiﬁcant improvements in symptoms for
men with late-onset hypogonadism. The long-term beneﬁts
and risks of testosterone-replacement therapy will become
clearer when the eﬀects of testosterone are studied on all
health-related outcomes over an extended period of time. A
NIH-sponsored large multicenter randomized control trial
of testosterone in aging men with low testosterone levels is
currentlyunderway.Thistrialmayprovideanswerstopoten-
tial beneﬁts and risks of testosterone replacement in aging
males. One limitation of this trial is that it is not powered to
fully assess potential risks of prostate cancer and cardiovas-
cular events.
If an aging male is diagnosed with late-onset hypogo-
nadism, the health care provider should engage in a discus-
sion regarding the beneﬁts and potential risks of testosterone
therapy in older men. Older men who have signiﬁcant ery-
throcytosis, untreated sleep apnea, prostate cancer, and high
risk of cardiovascular events should be excluded from testo-
sterone-replacement therapy. Currently, there is not enough
evidence to clearly state that the beneﬁts of testosterone-re-
placement therapy outweighs the risks of testosterone-re-
placement therapy in aging males. One cannot make a re-
commendationthattestosterone-replacementtherapycanbe
given to all aging males with low testosterone levels indepen-
dent of signiﬁcant signs or symptoms.
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